Location: United States, Illinois, Chicago
Total raised: $427M
Investors 1
| Date | Name | Website |
| 11.07.2025 | Revolution | revolution... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.05.2025 | Series D | $365M | - |
| 30.10.2024 | Series C | $62M | - |
Mentions in press and media 11
| Date | Title | Description |
| 04.08.2026 | Pathos AI Closes $2.3B Cancer Drug Deals to Prove AI Can Design Smarter Trials | By James Whitaker Published: Aug 04 2026, 3:03 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 15.05.2025 | AI-powered drug development startup Pathos AI closes $365M investment Your vote of support is important to us and it helps us keep the content FREE. One click below supports our mission to provide fre... | Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the investors in the Series D round. According to Fi... |
| 15.05.2025 | Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug | Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The company can now lay claim to a post-mone... |
| 31.10.2024 | Pathos AI: Pioneering the Future of Drug Development with $62M Boost | In the bustling heart of Chicago, a biotechnology company is reshaping the landscape of drug development. Pathos AI has recently secured $62 million in an oversubscribed Series C funding round. This infusion of capital is not just a financi... |
| 30.10.2024 | Pathos AI Closes $62M Series C Funding | Pathos AI, a Chicago, IL-based clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, raised $62M in Series C funding. The round was led by New Enterprise Associates (NEA) with parti... |
| 30.10.2024 | Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development | CHICAGO, I.L. Oct. 29, 2024 — Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of an oversubscribed $62M Series C funding round. The Se... |
| 29.10.2024 | Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development | CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of an oversubscribed $62M Series C funding ... |
| - | Pathos | “Reimagining drug discovery and development through the lens of technology, our data advantage fuels our AI intelligence platform.” |
| - | Pathos | “Pathos is a clinical-stage biotechnology company focused on re-engineering drug development with the power of advanced AI technologies.” |
| - | Manage your consent preferences Chicago-born biotech startup Pathos AI secures massive $365 million funding round | - |
Show more